Skip to main content
. 2017 Jul 24;127(8):3177–3188. doi: 10.1172/JCI93024

Figure 2. mRNA HBV–specific TCR–electroporated T cells show antiviral efficacy in vivo.

Figure 2

(A) Schematic representation of the experiment performed to assess the effect of 1 single injection of electroporated effector T cells in high viremic mice reconstituted with haplotype-matched hepatocytes. (B) Viremia changes relative to baseline levels determined after 4 and 6 days in individual mice upon 1 injection of mRNA HBV s183–TCR T cells (n = 5) and in untreated controls (n = 2). (C) ALT levels determined in HBV-infected and uninfected mice receiving a single injection of effector T cells. (D) Schematic representation of the experiment performed to assess the antiviral effect of multiple injections of electroporated effector T cells in high viremic mice reconstituted either with haplotype-matched (n = 3) or -mismatched (n = 3) human hepatocytes and in comparison with mice that were left untreated (n = 3). (E) Median viremia changes determined within each group depicted in D and relative to baseline levels determined in individual mice upon 3 injections of mRNA HBV s183–TCR T cells. Blood was taken 4, 8, and 12 days after the first T cell injection. (F) Median changes in levels of circulating HBeAg were determined by ELISA in all animal groups. BL, baseline.